Following a couple of fairly disastrous trial failures, Merck KGaA can finally celebrate a hit. The colony stimulating factor-1 (CSF-1) inhibitor pimicotinib, originated by China-based Abbisko and licensed to the German group, has shown an impressive response rate in its pivotal trial in tenosynovial giant cell tumor (TGCT), a rare, locally aggressive neoplasm of the joints.
Abbisko And Merck KGaA MANEUVER Pimicotinib Towards Approval
Pimicotinib’s Phase III data in tenosynovial giant cell tumor are better than its rivals but the fight for a small number of patients will be fierce.
More from Clinical Trials
• By
Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.
• By
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
More from Anticancer
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
• By
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.